Advanced search
Publication Cover
International Journal of Hyperthermia Volume 17, 2001 - Issue 6
Submit an article Journal homepage
106
Views
19
CrossRef citations to date
0
Altmetric
Research Article

Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid

R. Murata, J. Overgaard, M. R. Horsman
Pages 508-519 | Published online: 09 Jul 2009

  • Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metas Rev 1990; 9: 267-82.
  • Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999; 80 (SuppL 1): 57-64.
  • Ching L-M, Joseph WR, Zhuang L, Baguley BC. Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours. Cancer Chemother Pharmacol 1994; 35: 153-60.
  • Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 1994; 29: 373-7.
  • Laws AL, Matthew AM, Double JA, Bibby MC. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995; 71: 1204-9.
  • Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the anti- tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998; 78: 439-45.
  • Wilson WR, Li AE, Cowan DSM, Sum BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 1998; 42: 905-8.
  • Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching L-M. Stimulation of tumors to synthesize tumor necrosis factor-a in situ using 5,6-dimethylxanthenone-4acetic acid: a novel approach to cancer therapy. Cancer Res 1999; 59: 633-8.
  • Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 dis- odium phosphate and 5,6-dimethylxanthenone-4-acetc acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001; 77: 195-204.
  • Rewcastle GW, Atwell GJ, Zhuang L, Baguley BC, Denny WA. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 1991; 34: 217-22.
  • Mahadevan V, Malik ST, Meager A, Fiers W, Lewis GP, Hart IR. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res 1990; 50: 5537-42.
  • Ching L-M, Joseph WR, Crosier KE, Baguley BC. Induction of tumor necrosis factor-a messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 1994; 54: 870-2.
  • Kerr DJ, Maughan T, Newlands E, Rustin G, Bleehen NM, Lewis C, Kaye SB. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 1989; 60s: 104-6.
  • Bibby MC, Double JA, Loadman PM, Duke CV. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst 1989; 81: 216-20.
  • Hill SA, Williams KB, Denekamp J. Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. Eur J Cancer Clin Oncol 1989; 25: 1419-24.
  • Zwi LJ, Baguley BC, Gavin JB, Wilson WR. The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels. Br J Cancer 1990; 62: 231-7.
  • Horsman MR, Sampson LE, Chaplin DJ, Overgaard J. The in vivo interaction between flavone acetic acid and hypothermia. Int J Hyperthermia 1996; 12: 779-89.
  • Futami H, Eader LA, Komschlies KL, Bull R, Gruys ME, Ortaldo JR, Young HA, Wiltrout RH. Flavone acetic acid directly induces expression of cytokine genes in mouse splenic leukocytes but not in human peripheral blood leukocytes. Cancer Res 1991; 51: 6596-602.
  • Philpott M, Joseph WR, Crosier KE, Baguley BC, Ching L-M. Production of tumour necrosis factor-a by cultured human peripheral blood leucocytes in response to the anti- tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br J Cancer 1997; 76: 1586-91.
  • Crile G. The effects of heat and radiation on cancers implanted on the feet of mice. Cancer Res 1963; 23: 372-80.
  • Hill SA, Denekamp J. The effect of vascular occlusion on the thermal sensitization of a mouse tumour. Br J Radiology 1978; 51: 997-1002.
  • Wallen CA, Colby TV, Stewart JR. Cell kill and tumor control after heat treatment with and without vascular occlusion in RIF-I tumors. Radiat Res 1986; 106: 215-23.
  • Horsman MR, Christensen KL, Overgaard J. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo, hit J Hyperthermia 1989; 5: 123-36.
  • Kallinowski F, Moehle R, Vaupel P. Substantial enhancement of tumor hyperthermic response by tumor necrosis factor. In: Sugahara T, Saito M, eds. Hyperthermic Oncology Vol. I. London: Taylor and Francis, 1989: 258-9.
  • Kalmus J, Okunieff P, Vaupel P. Dose-dependent effects of hydralazine on microcircula- tory function and hyperthermic response of murine FSaII tumors. Cancer Res 1990; 50: 15-19.
  • Honess DJ, Hu DE, Blechen NM. A study of the mechanism of hydralazine enhancement of thermal damage in the KHT tumour. Int J Hyperthermia 1991; 7: 667-79.
  • Voorhees WD, Babbs CF. Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs. Eur J Cancer Clin Oncol 1982; 18: 1027-33.
  • Dewhirst MW, Prescott DM, Clegg S, Samulski TV, Page RL, Thrall DE, Leopold K, Rosner G, Acker JC, Oleson JR. The use of hydralazine to manipulate tumour tempera- tures during hypothermia. Int J Hyperthermia 1990; 6: 971-83.
  • Overgaard J, Nielsen OS. The role of tissue environmental factors on the kinetics and morphology of tumor cells exposed to hyperthermia. Ann N Y Acad Sci 1980; 335: 254-80.
  • Overgaard J, Bichel P. The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro. Radiology 1977; 123: 511-4.
  • Gerweck LE, Nygaard TG, Burlett M. Response of cells to hyperthermia under acute and chronic hypoxic conditions. Cancer Res 1979; 39: 966-72.
  • Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol 2001; 40: 497-503.
  • Oleson JR. Hyperthermia from the clinic to the laboratory: a hypothesis. Int J Hyperthermia 1995; 11: 315-22.
  • Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 1980; 6: 1507-17.
  • Sapirstein LA. Regional blood flow by fractional distribution of indicators. Am J Physiol 1958; 193: 161-8.
  • Horsman MR, Overgaard J, Chaplin DJ. The interaction between RSU-1069, hydralazine and hyperthermia in a C3H mammary carcinoma as assessed by tumour growth delay. Acta Oncol 1988; 27: 861-2.
  • Chaplin DJ, Horsman MR. The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies. Radiother Oncol 1994; 30: 59-65.
  • Parkins CS, Hill SA, Lonergan SJ, Horsman MR, Chadwick JA, Chaplin DJ. Ischaemia induced cell death in tumors: importance of temperature and pH. Int J Radiat Oncol Biol Phys 1994; 29: 499-503.
  • Gyldenhof B, Horsman MR, Overgaard J. Hyperthermia-induced changes in the vascularity and histopathology of a murine tumour and its surrounding normal tissue. In: Franconi C, Arcangeli G, Cavaliere R, eds. Hyperthermic Oncology Vol. II. Rome: Tor Vergata, 1996: 780-2.
  • Dewhirst MW, Prosnitz L, Thrall D, Prescott D, Clegg S, Charles C, MacFall J, Rosner G, Samulski T, Gillette E, LaRue S. Hyperthermic treatment of malignant diseases: current status and a view toward the future. Semin Oncol 1997; 24: 616-25.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.